{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:23:54Z","timestamp":1792873434993,"version":"4.5.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Biliary tract cancers (BTCs) contain several actionable molecular alterations, including FGFR2<\/jats:italic>, IDH1<\/jats:italic>, ERBB2<\/jats:italic> (formerly HER2<\/jats:italic>), and KRAS<\/jats:italic>. KRAS<\/jats:italic> allelic variants are found in 20% to 30% of BTCs, and multiple KRAS<\/jats:italic> inhibitors are currently under clinical investigation.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To describe the genomic landscape, co\u2013sequence variations, immunophenotype, genomic ancestry, and survival outcomes of KRAS<\/jats:italic>-mutated BTCs and to calculate the median overall survival (mOS) for the most common allelic variants.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective, multicenter, pooled cohort study obtained clinical and next-generation sequencing data from multiple databases between January 1, 2017, and December 31, 2022. These databases included Princess Margaret Cancer Centre, MD Anderson Cancer Center, Foundation Medicine, American Association for Cancer Research Project GENIE, and cBioPortal for Cancer Genomics. The cohort comprised patients with BTCs who underwent genomic testing.<\/jats:p><\/jats:sec>Main Outcome and Measure<\/jats:title>The main outcome was mOS, defined as date of diagnosis to date of death, which was measured in months.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 7457 patients (n\u2009=\u20093773 males [50.6%]; mean [SD] age, 63 [5] years) with BTCs and genomic testing were included. Of these patients, 5813 had clinical outcome data available, in whom 1000 KRAS<\/jats:italic>-mutated BTCs were identified. KRAS<\/jats:italic> allelic variants were highly prevalent in perihilar cholangiocarcinoma (28.6%) and extrahepatic cholangiocarcinoma (36.1%). Thirty-six KRAS<\/jats:italic> allelic variants were identified, and the prevalence rates in descending order were G12D (41%), G12V (23%), and Q61H (8%). The variant G12D had the highest mOS of 25.1 (95% CI, 22.0-33.0) months compared with 22.8 (95% CI, 19.6-31.4) months for Q61H and 17.8 (95% CI, 16.3-23.1) months for G12V variants. The majority of KRAS<\/jats:italic>-mutated BTCs (98.9%) were not microsatellite instability\u2013high and had low tumor mutational burden (ranging from a median [IQR] of 1.2 (1.2-2.5) to a mean [SD] of 3.3 [1.3]). Immune profiling through RNA sequencing of KRAS<\/jats:italic> and NRAS\u2013<\/jats:italic>mutated samples showed a pattern toward a more immune-inflamed microenvironment with higher M1 macrophage activation (0.16 vs 0.12; P<\/jats:italic>\u2009=\u2009.047) and interferon-\u03b3 expression compared with wild-type tumors. The G12D variant remained the most common KRAS<\/jats:italic> allelic variant in all patient ancestries. Patients with admixed American ancestry had the highest proportion of G12D variant (45.0%).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This cohort study found that KRAS<\/jats:italic> allelic variants were relatively common and may be potentially actionable genomic alterations in patients with BTCs, especially perihilar cholangiocarcinoma and extrahepatic cholangiocarcinoma. The findings add to the growing data on genomic and immune landscapes of KRAS<\/jats:italic> allelic variants in BTCs and are potentially of value to the planning of specific therapies for this heterogeneous patient group.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.9840","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T15:01:43Z","timestamp":1715007703000},"page":"e249840","source":"Crossref","is-referenced-by-count":34,"title":["KRAS<\/i> Allelic Variants in Biliary Tract Cancers"],"prefix":"10.1001","volume":"7","author":[{"given":"Gordon Taylor","family":"Moffat","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zishuo Ian","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"Department of Developmental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth Kathleen","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Pavlick","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc, Cambridge, Massachusetts"},{"name":"State University of New York Upstate Medical University, Syracuse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthikeyan","family":"Murugesan","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Kwong","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anaemy Danner","family":"De Armas","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Korkut","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"issue":"13","key":"zoi240360r1","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/cncr.v127.13","article-title":"The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"127","author":"Ouyang","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"zoi240360r2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.v73.1","article-title":"Cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"zoi240360r3","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7698786","article-title":"Contemporary tailored oncology treatment of biliary tract cancers.","volume":"2019","author":"Turkes","year":"2019","journal-title":"Gastroenterol Res Pract"},{"issue":"2","key":"zoi240360r4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s11894-011-0178-8","article-title":"Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis.","volume":"13","author":"Charbel","year":"2011","journal-title":"Curr Gastroenterol Rep"},{"issue":"10272","key":"zoi240360r5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer.","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"zoi240360r6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.","volume":"7","author":"Glimelius","year":"1996","journal-title":"Ann Oncol"},{"issue":"30","key":"zoi240360r7","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","article-title":"Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study.","volume":"28","author":"Sharma","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi240360r8","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"14","key":"zoi240360r9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi240360r10","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann Oncol"},{"key":"zoi240360r11","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00510","article-title":"Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures.","volume":"6","author":"Mody","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"zoi240360r12","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3390\/cancers12082039","article-title":"Targeted therapies in advanced biliary tract cancer: an evolving paradigm.","volume":"12","author":"Chakrabarti","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"16","key":"zoi240360r13","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1200\/JCO.2022.40.16_suppl.4114","article-title":"Clinical and genomic characterization of ERBB2-altered gallbladder cancer.","volume":"40","author":"Mondaca","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi240360r14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.37349\/etat","article-title":"Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy.","volume":"3","author":"Carotenuto","year":"2022","journal-title":"Explor Target Antitumor Ther"},{"issue":"24","key":"zoi240360r15","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1002\/cncr.v122.24","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management.","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"issue":"7","key":"zoi240360r16","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.ejso.2022.03.005","article-title":"Meta-analysis on prognostic value of KRAS mutation in resected mass-forming cholangiocarcinoma.","volume":"48","author":"Procopio","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"zoi240360r17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4137\/JCM.S40549","article-title":"KRAS mutation as a potential prognostic biomarker of biliary tract cancers.","volume":"7","author":"Yokoyama","year":"2016","journal-title":"Jpn Clin Med"},{"issue":"1","key":"zoi240360r18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","article-title":"Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma.","volume":"157","author":"Zhou","year":"2022","journal-title":"JAMA Surg"},{"issue":"36","key":"zoi240360r19","article-title":"KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRASG12C mutation.","volume":"41","author":"Yaeger","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi240360r20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1200\/JCO.2023.41.4_suppl.531","article-title":"Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.","volume":"41","author":"Bouattour","year":"2023","journal-title":"J Clin Oncol"},{"key":"zoi240360r21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.36_suppl.425082","article-title":"KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRAS G12C mutation.","volume":"41","author":"Pant","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi240360r22","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium.","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov"},{"issue":"6","key":"zoi240360r23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"3","key":"zoi240360r24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","article-title":"Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.","volume":"185","author":"Nguyen","year":"2022","journal-title":"Cell"},{"issue":"1","key":"zoi240360r25","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1038\/s41467-022-31780-9","article-title":"Landscape of somatic alterations in large-scale solid tumors from an Asian population.","volume":"13","author":"Wu","year":"2022","journal-title":"Nat Commun"},{"issue":"7667","key":"zoi240360r26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nature23306","article-title":"Integrative clinical genomics of metastatic cancer.","volume":"548","author":"Robinson","year":"2017","journal-title":"Nature"},{"issue":"11","key":"zoi240360r27","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"zoi240360r28","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00259","article-title":"Biological validation of RNA sequencing data from formalin-fixed paraffin-embedded primary melanomas.","author":"Kwong","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"zoi240360r29","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data.","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"zoi240360r30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT.","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol"},{"issue":"1","key":"zoi240360r31","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s42003-023-04777-3","article-title":"Mapping the functional interactions at the tumor-immune checkpoint interface.","volume":"6","author":"Bozorgui","year":"2023","journal-title":"Commun Biol"},{"issue":"3","key":"zoi240360r32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1158\/1078-0432.CCR-15-0876","article-title":"A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition.","volume":"22","author":"Mak","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"zoi240360r33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ccr.2013.06.004","article-title":"A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis.","volume":"24","author":"Masiero","year":"2013","journal-title":"Cancer Cell"},{"issue":"8","key":"zoi240360r34","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-?-related mRNA profile predicts clinical response to PD-1 blockade.","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"issue":"7571","key":"zoi240360r35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation.","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"issue":"6","key":"zoi240360r36","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1158\/0008-5472.CAN-11-3596","article-title":"Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.","volume":"72","author":"O\u2019Dell","year":"2012","journal-title":"Cancer Res"},{"issue":"1","key":"zoi240360r37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","article-title":"Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.","volume":"6","author":"Lee","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"zoi240360r38","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ccell.2020.04.012","article-title":"Comprehensive analysis of genetic ancestry and its molecular correlates in cancer.","volume":"37","author":"Carrot-Zhang","year":"2020","journal-title":"Cancer Cell"},{"issue":"16","key":"zoi240360r39","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1200\/JCO.2023.41.16_suppl.4088","article-title":"Characterizing KRAS allele variants within biliary tract cancers.","volume":"41","author":"Moffat","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi240360r40","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","article-title":"Expanding the reach of precision oncology by drugging all KRAS mutants.","volume":"12","author":"Hofmann","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"zoi240360r41","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12672-022-00550-w","article-title":"Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines.","volume":"13","author":"Plangger","year":"2022","journal-title":"Discov Oncol"},{"issue":"3","key":"zoi240360r42","doi-asserted-by":"publisher","first-page":"68","DOI":"10.36401\/JIPO-22-5","article-title":"Targeting KRAS: crossroads of signaling and immune inhibition.","volume":"5","author":"Kato","year":"2022","journal-title":"J Immunother Precis Oncol"},{"key":"zoi240360r43","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231170484","article-title":"The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.","author":"Jeong","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"issue":"7781","key":"zoi240360r44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"6","key":"zoi240360r45","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1158\/1535-7163.MCT-20-0462","article-title":"The KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy.","volume":"20","author":"Briere","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"zoi240360r46","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer.","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"zoi240360r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100360","article-title":"Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-na\u00efve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.","volume":"16","author":"J\u00e4nne","year":"2022","journal-title":"Immuno-Oncology and Technology"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2818363\/moffat_2024_oi_240360_1714140455.33174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T15:01:49Z","timestamp":1715007709000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2818363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.9840","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]}}}